Bipolar disorder: Leads from the molecular and cellular mechanisms of action of mood stabilisers

British Journal of Psychiatry

Volumn 178, Issue SUPPL. 141, 2001, Pages

  Manji, H K ^a   Moore, G J ^a   Chen, G ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM; VALPROIC ACID; GLYCOGEN SYNTHASE KINASE 3; PROTEIN KINASE (CALCIUM,CALMODULIN); PROTEIN KINASE C; TRANQUILIZER; TRANSCRIPTION FACTOR;

CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; NEUROPROTECTION; SIGNAL TRANSDUCTION; BIPOLAR DISORDER; GENE EXPRESSION REGULATION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTIMANIC AGENTS; BIPOLAR DISORDER; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0034981862     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.178.41.s107     Document Type: Conference Paper

References (141)

1. Molecular genetics of diabetes mellitus
2. Reduced brain inositol in lithium treated rats
3. Does lithium treatment still work? Evidence of stable responses over three decades
4. Effects of lithium treatment and its discontinuation in Bipolar Manic - Depressive Disorders
5. Second messenger systems and psychoactive drug action; focus on the phosphoinositide system and lithium
6. A preliminary investigation of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania
7. Linkage studies of bipolar illness
8. Inositol phosphates and cell signalling
9. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands
10. Neural and developmental actions of lithium: A unifying hypothesis
11. Emergent properties of networks of biological signaling pathways
12. A locus for bipolar affective disorder on chromosome 4p
13. Molecular machines integrate coincident synaptic signals
14. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity
15. Antidegenerative effects of Mg(2+)valproate in cultured cerebellar neurons
16. Mechanisms of action of lithium in affective illness: Basic and clinical implications
17. A risk-benefit assessment of tamoxifen therapy
18. Phosphoinositide metabolism and hormone action
19. Lithium decreases turnover of arachidonate in several brain phospholipids
20. Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro
21. Increase in AP-1 transcription factor DNA binding activity by valproic acid
22. Lithium increases tyrosine hydroxylase levels both in vivo and in vitro
23. Valproate robustly enhances AP-1 mediated gene expression
24. The mood stabilising agent valproate inhibits the activity of glycogen synthase kinase 3
25. The mood stabilising agents lithium and valproate robustly increase the expression of the neuroprotective protein bcl-2 in the CNS
26. Neurotransmitter receptors and phosphoinositide turnover
27. Protein kinase C in the nervous system
28. Clinical and radiographic response in patients with recurrent malignant gliomas treated with high-dose tamoxifen
29. A genome-wide search for human type 1 diabetes susceptibility genes
30. Mood stabilizers in the prevention of recurrent affective disorders: A meta-analysis
31. Application of tome-domain fitting in the quantification of in vivo IH spectroscopic imaging data sets
32. A functional anatomical study of unipolar depression
33. Subgenual prefrontal cortex abnormalities in mood disorders
34. A molecular and cellular theory of depression
35. Neuronal plasticity and survival in mood disorders
36. Meta-analyses of studies of ventricular enlargement and cortical suicidal prominence in mood disorders. Comparisons with controls of patients with schizophrenia
37. Inositol lipids and signal transduction in the nervous system: An update
38. Do animal models have a place in the genetic analysis of quantitative human behavioral traits?
39. Localised proton spectroscopy using stimulated echoes
40. Mood stabilizer combinations: A review of safety and efficacy
41. Genetic mapping using haplotype, association and linkage methods suggests a locus for severe bipolar disorder (BPI) at 18q22-q23
42. Altered platelet protein kinase C activity in bipolar affective disorder, manic episode
43. Genetics of bipolar affective disorder: Time for another reinvention?
44. A genome-wide search for chromosomal loci linked to bipolar affective disorder in the Old Order Amish
45. A genome-wide search for chromosomal loci linked to mental health wellness in relatives at high risk for bipolar affective disorder among the Old Order Amish
46. Potentiation by lithium of CMP-phosphatidate formation in carbachol-stimulated rat cerebral-cortical slices and its reversal by myo-inositol
47. Designing small-molecule switches for protein - Protein interactions
48. Linkage findings in bipolar disorder
49. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorders
50. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain
51. Activation of the Wnt signaling pathway: A molecular mechanism for lithium action
52. The mechanism of protein kinase C activation
53. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system
54. Initiation and adaptation: A paradigm for understanding psychotropic drug action
55. Axin, a negative regulator of the Wnt signalling pathway, forms a complex with GSK-3β and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin
56. Molecular mechanisms underlying mood-stabilization in manic-depressive illness: The phenotypic challenge
57. Programmed cell death and Bcl-2 protection in very low oxygen
58. Anti-bipolar therapy: Mechanism of action of lithium
59. AP-1 and NF-κB stimulated by carbachol in human neuroblastoma SH-SY5Y cells are differentially sensitive to inhibition by lithium
60. Lithium and brain signal transduction systems
61. A current view of tamoxifen for the treatment of breast cancer
62. Intrinsic transcriptional activation - Inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor alpha subunit revealed in the presence of the beta subunit
63. Control of transcription factors by signal transduction pathways: The beginning of the end
64. Neuroanatomical models and brain imaging studies
65. The AMLI/ETO fusion protein activates transcription of Bcl-2
66. A molecular mechanism for the effect of lithium on development
67. Intracerebroventricular myo-inositol antagonizes lithium-induced suppression of rearing behaviour in rats
68. Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression
69. Intricate regulation of tyrosine hydroxylase activity and gene expression
70. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in viva
71. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus
72. Signal transduction abnormalities in bipolar affective disorder
73. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction
74. Analysis of altered gene expression by differential display
75. Control of AP-1 activity by signal transduction cascades
76. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia
77. WNT-7A induces axonal remodelling and increases synapsin 1 levels in cerebellar neurons
78. G proteins: Implications for psychiatry
79. Monoaminergic mechanisms
80. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness
81. Signaling: Cellular insights into the pathophysiology of bipolar disorder
82. Lithium dramatically decreases mebrane-associated PKC in the hippocampus: Selectivity for the alpha isozyme
83. Signal transduction pathways. Molecular targets for lithium's actions
84. Modulation of PKC isozymes and substrates by lithium: The role of myo-inositol
85. Lithium at 50: Have the neuroprotective effects of this unique cation been overlooked?
86. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder
87. Neuroplasticity and cellular resilience in mood disorders. Millennium article
88. The cellular neurobiology of depression
89. Bcl-2 gene family in the nervous system
90. Temporal dissociation between lithium-induced CNS myo-inositol changes and clinical response in manic-depressive illness
91. Lithium increases N-acetyl-aspartate in the human brain: In vivo evidence in support of bcl-2's neurotrophic effects?
92. Lithium induced increase in human grey matter
93. Effects of lithium on second messenger systems in the brain
94. The effects of long-term lithium treatment on the mortality of patients with manic-depressive and schizoaffective illness
95. Lithium and the phosphoinositide cycle: An example of uncompetitive inhibition and its pharmacological consequences
96. Disruption of phosphoinositide signalling by lithium
97. Antidepressant treatment in the 21st century
98. Lithium therapy and suicide risk
99. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C
100. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx
101. Complex trait genetics: New methods yield a result for essential hypertension
102. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain
103. The inheritance of bipolar affective disorder: Abundant genes coming together
104. Desensitisation of muscarinic stimulated hippocampal cell firing is related to phosphoinositide hydrolysis and inhibited by lithium
105. Lithium, carbamazepine, and valproate in affective illness: Biological and neurobiological mechanisms
106. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells
107. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression
108. Role of phosphoinositides in transmembrane signalling
109. A manic depressive history
110. Signal sorting and amplification through G protein-coupled receptors
111. G protein-coupled receptor structure and function: The impact of disease causing mutations
112. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus caeruleus
113. The functional neuroanatomy of mood disorders
114. Abnormalities in G protein-coupled signal transduction pathways in human disease
115. Protein kinase C
116. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
117. The role of G proteins in transmembrane signalling
118. The genetics of hypertension
119. Evidence that a proconvulsant action of lithium is mediated by inhibition of myo-inositol phosphatase in mouse brain
120. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells
121. Time and frequency domain analysis of NMR data compared: An application to ID IH spectra of lipoproteins
122. Cellular phosphorylation of tau by GSK-3beta influences tau binding to microtubules and microtubule organisation
123. Lithium inhibition of protein kinase C activation induced serotonin release
124. Enhanced protein kinase C activity and translocation in bipolar affective disorder brains
125. Signal transduction abnormalities in bipolar disorder
126. The CBFbeta subunit is essential for CBF-alpha2 (AMLI) function in viva
127. Cloning and characterisation of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor
128. Guanine nucleotide binding (g) protein disturbances in bipolar affective disorder
129. Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: A property of protein kinase C-mediated mood stabilizers
130. Defective G proteins in human disease
131. Alteration of G protein expression or function in pathophysiology
132. G Protein mutations in human disease
133. Complexity in biological signaling systems
134. Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: Modulation by lithium
135. The axis-inducing activity, stability, and subcellular distribution of beta catenin is regulated in Xenopus embryos by glycogen synthase kinase 3
136. Lithium stimulates gene expression through the AP-1 transcription factor pathway
137. 2- terminal kinases (JNKs) in vitro and in the CNS in vivo